208 related articles for article (PubMed ID: 23404505)
1. The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.
Harris NC; Davydova N; Roufail S; Paquet-Fifield S; Paavonen K; Karnezis T; Zhang YF; Sato T; Rothacker J; Nice EC; Stacker SA; Achen MG
J Biol Chem; 2013 Mar; 288(12):8176-8186. PubMed ID: 23404505
[TBL] [Abstract][Full Text] [Related]
2. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
[TBL] [Abstract][Full Text] [Related]
3. Proteolytic processing of vascular endothelial growth factor-D is essential for its capacity to promote the growth and spread of cancer.
Harris NC; Paavonen K; Davydova N; Roufail S; Sato T; Zhang YF; Karnezis T; Stacker SA; Achen MG
FASEB J; 2011 Aug; 25(8):2615-25. PubMed ID: 21515745
[TBL] [Abstract][Full Text] [Related]
4. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2.
McColl BK; Paavonen K; Karnezis T; Harris NC; Davydova N; Rothacker J; Nice EC; Harder KW; Roufail S; Hibbs ML; Rogers PA; Alitalo K; Stacker SA; Achen MG
FASEB J; 2007 Apr; 21(4):1088-98. PubMed ID: 17242158
[TBL] [Abstract][Full Text] [Related]
5. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity.
Leppänen VM; Jeltsch M; Anisimov A; Tvorogov D; Aho K; Kalkkinen N; Toivanen P; Ylä-Herttuala S; Ballmer-Hofer K; Alitalo K
Blood; 2011 Feb; 117(5):1507-15. PubMed ID: 21148085
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
[TBL] [Abstract][Full Text] [Related]
7. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D.
McColl BK; Baldwin ME; Roufail S; Freeman C; Moritz RL; Simpson RJ; Alitalo K; Stacker SA; Achen MG
J Exp Med; 2003 Sep; 198(6):863-8. PubMed ID: 12963694
[TBL] [Abstract][Full Text] [Related]
8. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
Von Marschall Z; Scholz A; Stacker SA; Achen MG; Jackson DG; Alves F; Schirner M; Haberey M; Thierauch KH; Wiedenmann B; Rosewicz S
Int J Oncol; 2005 Sep; 27(3):669-79. PubMed ID: 16077915
[TBL] [Abstract][Full Text] [Related]
10. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
11. Structural determinants of growth factor binding and specificity by VEGF receptor 2.
Leppänen VM; Prota AE; Jeltsch M; Anisimov A; Kalkkinen N; Strandin T; Lankinen H; Goldman A; Ballmer-Hofer K; Alitalo K
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2425-30. PubMed ID: 20145116
[TBL] [Abstract][Full Text] [Related]
12. The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer.
Achen MG; Williams RA; Baldwin ME; Lai P; Roufail S; Alitalo K; Stacker SA
Growth Factors; 2002 Jun; 20(2):99-107. PubMed ID: 12148568
[TBL] [Abstract][Full Text] [Related]
13. Nuclear localization of vascular endothelial growth factor-D and regulation of c-Myc-dependent transcripts in human lung fibroblasts.
El-Chemaly S; Pacheco-Rodriguez G; Malide D; Meza-Carmen V; Kato J; Cui Y; Padilla PI; Samidurai A; Gochuico BR; Moss J
Am J Respir Cell Mol Biol; 2014 Jul; 51(1):34-42. PubMed ID: 24450584
[TBL] [Abstract][Full Text] [Related]
14. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium.
Karnezis T; Shayan R; Caesar C; Roufail S; Harris NC; Ardipradja K; Zhang YF; Williams SP; Farnsworth RH; Chai MG; Rupasinghe TW; Tull DL; Baldwin ME; Sloan EK; Fox SB; Achen MG; Stacker SA
Cancer Cell; 2012 Feb; 21(2):181-95. PubMed ID: 22340592
[TBL] [Abstract][Full Text] [Related]
15. [Vascular endothelial growth factor (VEGF)-D in association with VEGF receptor-3 in lymphatic metastasis of breast cancer].
Chen YN; Gu Y
Ai Zheng; 2009 Dec; 28(12):1337-43. PubMed ID: 19958632
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance.
Achen MG; Stacker SA
Growth Factors; 2012 Oct; 30(5):283-96. PubMed ID: 22817635
[TBL] [Abstract][Full Text] [Related]
17. Molecular control of lymphatic metastasis.
Achen MG; Stacker SA
Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
19. Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis.
Matsumoto M; Roufail S; Inder R; Caesar C; Karnezis T; Shayan R; Farnsworth RH; Sato T; Achen MG; Mann GB; Stacker SA
Clin Exp Metastasis; 2013 Aug; 30(6):819-32. PubMed ID: 23591595
[TBL] [Abstract][Full Text] [Related]
20. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
Chen HM; Tsai CH; Hung WC
Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
